rocky89
rocky89 / iStockphoto.com
10 January 2018Big Pharma

Allergan tries to escape Restasis IPRs

Allergan is attempting to remove itself from a series of inter partes reviews focused on dry eye treatment Restasis (cyclosporine ophthalmic emulsion).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
8 January 2018   The Patent Trial and Appeal Board has denied an information request by a Native American tribe, deeming it improper for a number of reasons.
Americas
19 January 2018   Generics company Mylan Pharmaceuticals has resisted Allergan’s attempt to withdraw itself from a series of inter partes reviews (IPRs) relating to patents covering dry-eye medication Restasis (cyclosporine ophthalmic emulsion).
Americas
29 March 2018   The US Court of Appeals for the Federal Circuit has ordered the Patent and Trial Appeal Board to halt its review of patents covering a dry eye medication while the court considers arguments that tribal immunity protects the patents from board proceedings.

More on this story

Americas
8 January 2018   The Patent Trial and Appeal Board has denied an information request by a Native American tribe, deeming it improper for a number of reasons.
Americas
19 January 2018   Generics company Mylan Pharmaceuticals has resisted Allergan’s attempt to withdraw itself from a series of inter partes reviews (IPRs) relating to patents covering dry-eye medication Restasis (cyclosporine ophthalmic emulsion).
Americas
29 March 2018   The US Court of Appeals for the Federal Circuit has ordered the Patent and Trial Appeal Board to halt its review of patents covering a dry eye medication while the court considers arguments that tribal immunity protects the patents from board proceedings.

More on this story

Americas
8 January 2018   The Patent Trial and Appeal Board has denied an information request by a Native American tribe, deeming it improper for a number of reasons.
Americas
19 January 2018   Generics company Mylan Pharmaceuticals has resisted Allergan’s attempt to withdraw itself from a series of inter partes reviews (IPRs) relating to patents covering dry-eye medication Restasis (cyclosporine ophthalmic emulsion).
Americas
29 March 2018   The US Court of Appeals for the Federal Circuit has ordered the Patent and Trial Appeal Board to halt its review of patents covering a dry eye medication while the court considers arguments that tribal immunity protects the patents from board proceedings.